Abstract
Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P and T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P and T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 520-531 |
| Number of pages | 12 |
| Journal | Formulary |
| Volume | 30 |
| Issue number | 9 |
| State | Published - 1995 |
ASJC Scopus subject areas
- Pharmaceutical Science
Fingerprint Dive into the research topics of 'Developing guidelines for biotechnology drug use: Experience with antithrombin III'. Together they form a unique fingerprint.
Cite this
Romac, D. R., Poole, P., Owings, J. T., Mahackian, K., Foulke, G., Tharratt, R. S., & Albertson, T. E. (1995). Developing guidelines for biotechnology drug use: Experience with antithrombin III. Formulary, 30(9), 520-531.